7. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy 8. Known hypersensitivity to the study drugs 9. History of prior malignancy, unless the malignancy had been treated with a curative intent and in remission without treatment for ≥5 years prior to enrollment, and with the exception of curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, low-grade in situ carcinoma of the cervix and low-grade, early-stage localized prostate cancer treated surgically with curative intent 10. Regular treatment (i.e. >5 consecutive days) with corticosteroids during the 28 days prior to the start of cycle 1, day 1, unless administered for indications other than CLL at a dose of prednisone ≤30 mg/day or equivalent 11. Regular treatment with immunosuppressive medications following previous organ transplantation 12. Evidence of significant, uncontrolled co-existing diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, severe arrhythmia, myocardial infarction within the previous 6 20. Women who were pregnant or lactating 21. Fertile men or women of childbearing potential unless: (1) surgically sterile or ≥2 years after the onset of menopause; (2) willing to use a highly effective contraceptive method (Pearl Index <1) -such as oral contraceptives, an intrauterine device, sexual abstinence or a barrier method of contraception in conjunction with spermicidal jelly -during study treatment and in female patients for 12 months after the end of antibody treatment and in male patients for 6 months after the end of chemotherapy treatment 22. Participation in another clinical trial with drug intervention within 28 days prior to the start of cycle 1, day 1 and during the study.
Chemotherapy
The choice of chemotherapy was at the investigator's discretion based on the fitness of the patient, commercial availability of permitted agents, possible previous treatment with obinutuzumab (G) and accepted local practice. Chemotherapy options were fludarabine/cyclophosphamide (25/250 mg/m 2 intravenously or 40/250 mg/m 2 orally on days 1-3; G-FC) for fit patients only (defined as a CIRS score of ≤6 and CrCl ≥70 mL/minute [min]), chlorambucil (0.5 mg/kg orally on days 1 and 15; G-Clb) for unfit patients (defined as a CIRS score of >6 and/or CrCl <70 mL/min) only or bendamustine (benda) for any patient (70 mg/m 2 [relapsed/refractory {R/R} patients] or 90 mg/m 2 [first-line] on days 1 and 2; 50 or 70 mg/m 2 was permitted as a starting dose for R/R patients and unfit first-line patients, respectively; G-benda). Patients who had relapsed after, or who were refractory to, previous obinutuzumab monotherapy (G-mono) had to receive obinutuzumab with chemotherapy.
Switching chemotherapy was not allowed during the study.
Granulocyte colony-stimulating factor (G-CSF) was used for prophylaxis of neutropenia, to be administered according to institutional guidelines, e.g. those of the American Society of Clinical Oncology. Platelet transfusions could be used in cases of thrombocytopenia according to institutional practice, at the discretion of the treating physician. Antimicrobial prophylaxis was not mandated by the study protocol in GREEN but could be given at the investigator's discretion in accordance with local guidelines.
Infusion-related reaction mitigation cohorts
While the primary objective of the study was to evaluate safety/tolerability, a prespecified exploratory objective was to investigate approaches to mitigate or prevent infusion-related reactions (IRRs) in first-line patients, in whom the first dose of obinutuzumab was administered over 2 days. Three cohorts were enrolled sequentially and were treated, as follows:
 Cohort 1, 25 mg at 12.5 mg/hour (h) on day 1 and 975 mg at 50-400 mg/h on day 2;  Cohort 2, 100 mg at 25 mg/h on day 1 and 900 mg at 50-400 mg/h on day 2, with oral dexamethasone 20 mg or equivalent given 12 h pre-dose;  Cohort 3, in which doses/infusion rates were as Cohort 1 and pre-medication was as
In R/R patients, obinutuzumab was administered according to the label (100 mg at 25 mg/h on day 1 and 900 mg at 50-400 mg/h on day 2 of cycle 1). 2, 3 In addition to these measures, all patients received intravenous prednisolone (or equivalent) 1 h pre-dose on cycle 1, day 1/day 2. Pre-medication with acetaminophen and an antihistamine was also stipulated approximately 30 min prior to the start of the obinutuzumab infusion on cycle 1 day 1/day 2.
Safety data relating to IRRs were reviewed in each cohort when approximately 150 patients had completed at least one cycle of obinutuzumab.
Tumor lysis syndrome risk minimization measures

Risk minimization measures, including prophylaxis (allopurinol [or a suitable alternative]
and appropriate hydration) and investigator training, were instigated for patients considered at risk of tumor lysis syndrome (TLS), defined initially as those with a tumor burden ≥10 cm, or ≥5 but <10 cm with lymphocytes ≥25×10 9 /L. G-CSF use was allowed; primary prophylaxis was advised for patients aged ≥60 years and/or with comorbidities. Allopurinol or a suitable alternative (e.g. rasburicase) was started at least 72 h prior to the first infusion of obinutuzumab on cycle 1, day 1. Hydration consisted of an oral fluid intake of approximately 3 L/day, starting 1-2 days before the first dose of obinutuzumab. Patients still considered at risk of TLS because of a persistently high tumor burden (i.e. lymphocytes ≥25×10 9 /L) before the second and subsequent infusions of obinutuzumab could continue to receive TLS prophylaxis and adequate hydration until the risk had abated, as determined by the investigator.
Patients considered at risk of TLS were monitored carefully during the initial stages of study treatment particularly with respect to their renal function, potassium and uric acid values.
Chemotherapy was not resumed until all symptoms of TLS (clinical or laboratory) had disappeared.
Following the occurrence of two fatal TLS cases in patients treated with G-benda, the definition of TLS risk was expanded (by protocol amendment) for patients receiving the Gbenda combination, as follows: 
Secondary outcome measures
Secondary efficacy outcome measures in the GREEN study included: 
Results
Late reporting
After the data snapshot was taken for analysis, a further 52 adverse events in 42 patients (AEs; 0.5% of total AEs) were reported late by the sites for the initial cut-off day on the database, which remained open to continue collecting information until the final analysis. Similarly, responses at the final analysis were reclassified in 11/971 (1.1%) patients.
These updates are not part of the statistical analysis summary tables and listings, as they were reported after the analysis was done. A review was completed and suggested no impact on the safety and overall efficacy conclusions. These updates were not included in the statistical analysis summary tables; listings for the primary analysis will be done at the time of final analysis of the study.
The 52 additional AEs included 26 grade ≥3 AEs (19 grade 3 and seven grade 4 AEs, including eight grade ≥3 neutropenia events) and 11 serious AEs (dyspnea, febrile neutropenia, headache, hemorrhagic stroke, hepatitis E, influenza, invasive pulmonary aspergillosis, lung infection, polytrauma, sepsis and squamous cell cancer; each n=1).
Response status was amended in 11 patients, as follows (by study treatment): G-FC (one CR to CRi and two CR to PR), G-Clb (one CR to PR and one stable disease [SD] to PR), G-benda (three CR to PR, one SD to PR, one PR to CR and one progressive disease [PD] to PR) and Gmono (no changes). The overall conclusions from GREEN were not considered to have been impacted by this late reporting. 
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